Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanja Fehm

Showing results (281-290 of 371) with videos related to

Pageof 38
Sort By:
Cancers|December 10, 2021
Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer PatientsAndré Franken, Bianca Behrens, Florian Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Cytometry. Part B, Clinical Cytometry|February 22, 2011
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility studyJaco Kraan, Stefan Sleijfer, Michiel H Strijbos, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 11, 2020
Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancerJan Haussmann, Carolin Nestle-Kraemling, Edwin Bölke, et al.
Clinical Breast Cancer|March 31, 2018
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR StudyNikola S Mutschler, Christoph Scholz, Thomas W P Friedl, et al.
The Journal of Molecular Diagnostics : JMD|November 1, 2019
Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer PatientsAndré Franken, Ellen Honisch, Florian Reinhardt, et al.
Journal of the National Cancer Institute|October 13, 2018
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisElisabeth Trapp, Wolfgang Janni, Christian Schindlbeck, et al.
JCO Precision Oncology|February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast CancerAmelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA TrialGuillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, et al.
Pageof 38

Showing results (281-290 of 371) with videos related to

Sort By:
Pageof 38
Cancers|December 10, 2021
Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer PatientsAndré Franken, Bianca Behrens, Florian Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Cytometry. Part B, Clinical Cytometry|February 22, 2011
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility studyJaco Kraan, Stefan Sleijfer, Michiel H Strijbos, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 11, 2020
Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancerJan Haussmann, Carolin Nestle-Kraemling, Edwin Bölke, et al.
Clinical Breast Cancer|March 31, 2018
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR StudyNikola S Mutschler, Christoph Scholz, Thomas W P Friedl, et al.
The Journal of Molecular Diagnostics : JMD|November 1, 2019
Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer PatientsAndré Franken, Ellen Honisch, Florian Reinhardt, et al.
Journal of the National Cancer Institute|October 13, 2018
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisElisabeth Trapp, Wolfgang Janni, Christian Schindlbeck, et al.
JCO Precision Oncology|February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast CancerAmelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA TrialGuillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, et al.
Pageof 38